Living with Type 1 diabetes is a numbers game. There’s not a moment in the day free from the burden of tracking your blood ...

Dexcom bet on the high financial ceiling that exists by integrating its glucose monitoring capabilities into the ring, culminating in a $75m investment in Ō ...

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Dexcom (Nasdaq:DXCM) announced today that it plans to establish a direct presence in Italy, bringing its CGM technology to ...

Technology can make that question easier to ask and answer, but for T1D patients, especially the kids who the disease ... which integrates easily into the Dexcom CGM ecosystem, seems an obvious ...

DexCom (NASDAQ:DXCM) shares popped 6% premarket ... This outlook considers sensor volume growth driven by increasing CGM access and awareness for people with diabetes, the continued rollout ...

Strong Product Demand: We are upbeat about DexCom's continued strength in CGM products. DexCom demonstrated strong product demand in third-quarter 2024, highlighted by record new patient starts in ...

Dexcom’s focus on expanding continuous glucose monitoring access, rolling out new products like the Stelo, and its plans for international growth suggest promising opportunities for future ...

Redburn Atlantic upgraded DexCom (DXCM) to Buy from Neutral with a price target of $115, up from $85. The company is positioned to benefit from ...

SAN FRANCISCO—After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have diabetes, Dexcom said it expects to see more than $4.03 ...